Related Experiment Video
Updated: Aug 6, 2026

07:30
Robot-Assisted Kidney Transplantation
Published on: July 19, 2021
Robot-assisted Partial Nephrectomy with the new HugoRAS System: single center matched-pair analysis
Guilherme Guimarães Gonçalves1, Nuno Vinagre1, Martinha Magalhães1
1Departamento de Urologia, Unidade Local de Saúde de Santo António, Porto, Portugal.
Summary
The new Hugo™ robotic-assisted partial nephrectomy (RAPN) shows comparable oncological and functional outcomes to traditional laparoscopic partial nephrectomy (LPN). This robotic approach offers a shorter hospital stay without increasing complications.
Area of Science:
- Urology
- Surgical Oncology
- Robotic Surgery
Background:
- Robotic-assisted surgery (RAS) is advancing kidney-sparing procedures.
- Comparisons between new robotic platforms and conventional laparoscopy are crucial for clinical adoption.
- The Hugo™ RAS system is a novel platform for urological procedures.
Purpose of the Study:
- To compare oncological, perioperative, and functional outcomes of robot-assisted partial nephrectomy (RAPN) using the Hugo™ RAS system versus laparoscopic partial nephrectomy (LPN).
- To evaluate the safety and effectiveness of the Hugo™ RAS system in partial nephrectomy within a tertiary care setting.
Main Methods:
- Retrospective single-center study of 165 patients undergoing LPN (n=95) or RAPN (n=70).
- Propensity score matching (1:1) was used to create comparable groups.
- Oncological, perioperative, and functional outcomes, including trifecta and pentafecta success rates, were assessed.
Main Results:
- After matching, 70 patients were in each group; no significant differences in operative time, warm ischemia time (WIT), or estimated blood loss.
- RAPN was associated with a shorter length of stay (3 vs. 5 days, p<0.001) and similar complication rates.
- Renal function preservation (≥90% eGFR) and trifecta/pentafecta achievement rates were comparable between LPN and RAPN.
Conclusions:
- The Hugo™ RAS system demonstrates effectiveness and safety for partial nephrectomy, matching LPN outcomes.
- The study supports the use of the Hugo™ RAS platform for kidney-sparing surgery without compromising oncological or functional results.
